Why Amgen Is Buying Onyx for $10.4B
Aug. 26 (Bloomberg) -- Amgen agreed to buy Onyx Pharmaceuticals in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue. Olivia Sterns reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Most Recent Videos
Is Political Risk Premium Being Priced Into U.S. Assets?
41:12 - UniCredit Research Head of Global FX Vasileios Gkionakis discusses the political risk premium associated with President Trump, the dollar and unemployment. He speaks with on "Bloomberg Markets.” (Source: Bloomberg)